Sirnaomics Ltd. · HKEX:2257

Sirnaomics — Technical Presentation (March 2022)

31 slides from Sirnaomics's technical presentation, Mar 15, 2022

  1. Slide 1: GalAhead Platform & Programs

    Slide 1: GalAhead Platform & Programs

    Sirnaomics Ltd. GalAhead™ Platform & Programs March 15, 2022 Boston 0

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    Disclaimer By attending the meeting where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: The information in this presentation has been prepared by representatives of Sirnaomics Ltd. (the “Company”) for use in presentations by

  3. Slide 3: Sirnaomics: Introduction

    Slide 3: Sirnaomics: Introduction

    Sirnaomics: Introduction Proprietary First RNAi Broad Technology therapeutic utility driven platforms Successful fund delivery platforms oncology success Oncology, fibrosis, ▪Proprietary algorithm for raising Proprietary PNP and First to achieve siRNA drug design Raised >$300M since medical aestheti

  4. Slide 4: Peptide Nanoparticle (PNP) Technology: Principles

    Slide 4: Peptide Nanoparticle (PNP) Technology: Principles

    Peptide Nanoparticle (PNP) Technology: Principles PNP delivery Self-Assembled Nanoparticle • Biodegradable histidine-lysine branched polymer • Envelops and protects siRNA to facilitate delivery into the targeted tissue and cell Histidine-Lysine 80-120nm • Histidine mediated protonation to facilitate

  5. Slide 5: Sirnaomics: Programs

    Slide 5: Sirnaomics: Programs

    Sirnaomics: Programs Delivery IND Candidate Gene Targets Indications Pre-clinical IND Phase I Phase II Phase III Rights Platform Enabling 2 in clinical isSCC US Global stage China (MRCT)2 BCC US Global STP705* TGF-β1/COX-2 PNP-IT US Liver Cancer1 (Basket) ** Global 8 in IND China (MRCT)3 enabling Li

  6. Slide 6: GalAhead: Sirnaomics' proprietary GalNAc-siRNA platform

    Slide 6: GalAhead: Sirnaomics' proprietary GalNAc-siRNA platform

    GalAhead™: Sirnaomics’ proprietary GalNAc-siRNA platform GalAhead™ technology incorporates multiple components mxRNA™: miniaturized single-targeting RNAi triggers muRNA™: multi-unit multi-targeting RNAi triggers NB: pronounced as in Sir Galahad, a knight of the King Arthur's Round Table and one of o

  7. Slide 7: mxRNAs: Proposed mechanism of action (MOA)

    Slide 7: mxRNAs: Proposed mechanism of action (MOA)

    mxRNAs™: Proposed mechanism of action (MOA) antisense antisense GalNAc adaptor Single oligo 29-33 nt long RISC RISC target mRNA cleavage 6

  8. Slide 8: mxRNA: Remarkable activity in primary hepatocytes

    Slide 8: mxRNA: Remarkable activity in primary hepatocytes

    mxRNA™: Remarkable activity in primary hepatocytes Sequence 1 Variant–1 Variant–2 Variant–3 IC70 = 0.47 nM IC70 = 0.64 nM IC70 = 0.85 nM Max KD = 81% Max KD = 76% Max KD = 82% Sequence 2 X84961 X84962 X84963 1.2 Variant–1 1.2 Variant–2 1.2 Variant–3 IC70 = 0.84 nM IC70 = 0.85 nM IC70 = 0.93 nM 1 1 1

  9. Slide 9: mxRNA: Outstanding in vivo activity (single dose)

    Slide 9: mxRNA: Outstanding in vivo activity (single dose)

    mxRNA™: Outstanding in vivo activity (single dose) Animals: mice Dose: 10 mg/kg Timepoint: 5 days Readout: TMPRSS6 mRNA Statistics: One-Way ANOVA Post-hoc analysis with Tukey’s multiple comparisons test **** = p<0.0001 8

  10. Slide 10: mxRNA: Outstanding in vivo activity (dose response)

    Slide 10: mxRNA: Outstanding in vivo activity (dose response)

    mxRNA™: Outstanding in vivo activity (dose response) Study Design • 1, 2 & 3 configuration for sequence 1 • Doses: 1.25 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg • N= 4 C57/Bl6 mice/group • 5 day timepoint • bDNA analysis: TMPRSS6 mRNA from liver tissues Statistics: One-Way ANOVA Post-hoc analysis with Tu

  11. Slide 11: mxRNA: Outstanding in vivo activity (duration response)

    Slide 11: mxRNA: Outstanding in vivo activity (duration response)

    mxRNA™: Outstanding in vivo activity (duration response) Study Design • 1, 2 & 3 configuration for sequence 1 • Dose: 3mg/kg • N= 4 C57/Bl6 mice/group • Timepoints: 3-day, 1-week, 3- week, 6-week • bDNA analysis: TMPRSS6 mRNA from liver tissues Statistics: One-Way ANOVA Post-hoc analysis with Tukey’

  12. Slide 12: mxRNA: Potential CMC advantage

    Slide 12: mxRNA: Potential CMC advantage

    mxRNA™: Potential CMC advantage Passenger (sense strand) Design Rules Constant sequence [?] Constant sequence Guide (antisense strand) Design Rules • Synthesis one: 36 nucleotides • Synthesis two: 20 nucleotides • Annealing • Synthesis one: 31-33 nucleotides Note: 1. In November 2021, Novo Nordisk a

  13. Slide 13: mxRNA: Potential advantage package

    Slide 13: mxRNA: Potential advantage package

    mxRNA™: Potential advantage package Outstanding activity Relative ease of CMC mxRNA™ Solid IP position (protection and FTO) 12

  14. Slide 14: GalAhead Programs: March 2022

    Slide 14: GalAhead Programs: March 2022

    GalAhead™ Programs: March 2022 Candidate IND Drug Target Indication Bioinformatics Discovery IND Nomination Enabling STP122G Factor XI Anticoagulation/Thrombosis STP125G Non-disclosed Hypertriglyceridemia Complement Complement-mediated STP144G Factor B diseases STP135G Non-disclosed Hypercholesterol

  15. Slide 15: STP125G (non-disclosed target)

    Slide 15: STP125G (non-disclosed target)

    STP125G (non-disclosed target) 14

  16. Slide 16: Humanized liver mouse model

    Slide 16: Humanized liver mouse model

    Humanized liver mouse model 20% mouse mouse liver 80% human human hepatocytes Source: M. Grompe and S. Strom (2013) Gastroenterology, 145:1209–1214 15

  17. Slide 17: STP125G: Humanized liver mice study design

    Slide 17: STP125G: Humanized liver mice study design

    STP125G: Humanized liver mice study design Humanized Liver Mice Animals: • humanized mice Treatment N = 36 mice total All Groups • N = 4 per group Treatment & sample collection site: • DaVinci (MA) Test compounds: • A28(14-4)mF mxRNA • A277(12-5) mxRNA Dosing: • 10 mg/kg Day 0 Day 14 Week 6 • 30 mg/

  18. Slide 18: STP125G: Dose response in vivo (Week 2)

    Slide 18: STP125G: Dose response in vivo (Week 2)

    STP125G: Dose response in vivo (Week 2) 160 140 Percent change as compared to control 120 (Mean +SD) 100 80 60 56% 87% 73% 87% 40 88% 90% 92% 98% 20 0 PBS A28 (14-4)mF- A28(14-4)mF-30 A277(12-5)-10 A277(12-5)-30 10 mRNA Protein 17

  19. Slide 19: STP125G: Knockdown duration

    Slide 19: STP125G: Knockdown duration

    STP125G: Knockdown duration mRNA levels in liver tissues Protein levels in plasma (ELISA) 160 160 140 140 Percent change as compared to control Percent change as compared to control 120 120 100 100 (Mean + SD) (Mean + SD) 80 80 60 60 40 40 20 20 0 0 Control A28(14-4)mF A277(12-5) Control A28(14-4)mF

  20. Slide 20: STP144G (Complement Factor B)

    Slide 20: STP144G (Complement Factor B)

    STP144G (Complement Factor B) 19

  21. Slide 21: STP144G: Non-human primates (NHP) study design

    Slide 21: STP144G: Non-human primates (NHP) study design

    STP144G: Non-human primates (NHP) study design 20

  22. Slide 22: Complement Factor B: Bb assay background

    Slide 22: Complement Factor B: Bb assay background

    Complement Factor B: Bb assay background From Midler FJ et al (2007) Nat Struct & Mol Biol (14) 224–8 21

  23. Slide 23: STP144G: Bb levels with lead compounds in NHP

    Slide 23: STP144G: Bb levels with lead compounds in NHP

    STP144G: Bb levels with lead compounds in NHP Single Treatment Comparison Multiple Treatment Comparison BLQ BLQ Range Range Days Days Max reduction of Factor Bb and duration of response Max reduction of Factor Bb and duration of response • 106-13(4) • 106-13(4) ─ Max suppression of 74% at week 5 ─ M

  24. Slide 24: STP122G (Coagulation Factor XI)

    Slide 24: STP122G (Coagulation Factor XI)

    STP122G (Coagulation Factor XI) 23

  25. Slide 25: Factor XI: Knockdown in non-human primates (NHP) study design

    Slide 25: Factor XI: Knockdown in non-human primates (NHP) study design

    Factor XI: Knockdown in non-human primates (NHP) study design 24

  26. Slide 26: Factor XI (NHP): Primary activity readout (up to week 33)

    Slide 26: Factor XI (NHP): Primary activity readout (up to week 33)

    Factor XI (NHP): Primary activity readout (up to week 33) All groups Groups: 2x, 3x Group: 3x 25

  27. Slide 27: Factor XI (NHP): Secondary activity readout and pathway specificity

    Slide 27: Factor XI (NHP): Secondary activity readout and pathway specificity

    Factor XI (NHP): Secondary activity readout and pathway specificity Extrinsic Pathway: Intrinsic Pathway: Prothrombin time test (PT) Activated Partial Thromboplastin Time test (APTT) The prothrombin test specifically evaluates the presence of APTT measures the integrity of the intrinsic system facto

  28. Slide 28: Factor XI (NHP): Secondary activity readout and pathway specificity

    Slide 28: Factor XI (NHP): Secondary activity readout and pathway specificity

    Factor XI (NHP): Secondary activity readout and pathway specificity APTT PT • Reductions in plasma FXI activity correlated well with elevation of APTT • No effect on PT values • Dose dependent elevation of APTT 27

  29. Slide 29: Factor XI (NHP): Safety readouts

    Slide 29: Factor XI (NHP): Safety readouts

    Factor XI (NHP): Safety readouts Baseline Week 2 Week 6 Week 18 Week 26 Week 33 (pre-treatment) (2 weeks post-treatment) Control 10mg/kg 3mg/kg (3x) Control 10mg/kg 3mg/kg (3x) Control 10mg/kg 3mg/kg (3x) Control 10mg/kg 3mg/kg (3x) Control 10mg/kg 3mg/kg (3x) Control 10mg/kg 3mg/kg (3x) (Mean ± SD)

  30. Slide 30: GalAhead Programs: March 2022

    Slide 30: GalAhead Programs: March 2022

    GalAhead™ Programs: March 2022 Candidate IND Drug Target Indication Bioinformatics Discovery IND Nomination Enabling STP122G Factor XI Anticoagulation/Thrombosis STP125G Non-disclosed Hypertriglyceridemia Complement Complement-mediated STP144G Factor B diseases STP135G Non-disclosed Hypercholesterol

  31. Slide 31: Questions?

    Slide 31: Questions?

    P- Questions? Simna@mics icing RNAi Therapeutics. 30

Source: Internet Archive copy of sirnaomics.com

More decks from Sirnaomics Ltd.

All 11 Sirnaomics decks